(a) As used in this section, and sections 19a-110a to 19a-111k, inclusive:

Ask a legal question, get an answer ASAP!
Click here to chat with a lawyer about your rights.

(1) “Abatement” means any set of measures designed to reduce or eliminate lead hazards, including, but not limited to, the encapsulation, replacement, removal, enclosure or covering of paint, plaster, soil or other material containing toxic levels of lead and all preparation, clean-up, disposal and reoccupancy clearance testing;

(2) “Epidemiological investigation” means an examination and evaluation by a lead inspector certified under chapter 400c to determine the cause of elevated blood levels, detect lead-based paint and report findings and (A) includes (i) an on-site inspection and, if applicable, an inspection of other dwellings or areas frequented by a person with elevated blood lead levels that may be the source of a lead hazard, and (ii) an evaluation of other potential sources of lead hazards, including, but not limited to, drinking water, soil, dust, pottery, gasoline, toys or occupational exposure, and (B) may include isotopic analysis of lead-containing items;

(3) “Lead screening” means a blood lead test from a finger-prick or venous blood draw;

(4) “On-site inspection” means an examination of a residential dwelling to identify lead hazards, including, but not limited to, an examination of the dwelling for deteriorating paint, lead dust, bare soil near the perimeter of the dwelling, household items that may present a potential lead risk, such as toys, cookware, food products and cosmetics, and an inquiry into the water system serving the dwelling;

(5) “Remediation” means the process of remedying a lead hazard condition, including, but not limited to, investigation, abatement and, if appropriate, ongoing management measures; and

(6) “Risk assessment” means the collection of information about a person’s potential lead exposures and a determination of whether such person has an increased likelihood of an elevated blood lead level.

(b) Not later than forty-eight hours after receiving or completing a report of a person found to have a level of lead in the blood equal to or greater than three and one-half micrograms per deciliter of blood or any other abnormal body burden of lead, each institution licensed under sections 19a-490 to 19a-503, inclusive, and each clinical laboratory licensed under section 19a-565 shall report to (1) the Commissioner of Public Health, and to the director of health of the town, city, borough or district in which the person resides: (A) The name, full residence address, date of birth, gender, race and ethnicity of each person found to have a level of lead in the blood equal to or greater than three and one-half micrograms per deciliter of blood or any other abnormal body burden of lead; (B) the name, address and telephone number of the health care provider who ordered the test; (C) the sample collection date, analysis date, type and blood lead analysis result; and (D) such other information as the commissioner may require, in a form and manner as prescribed by the commissioner, and (2) the health care provider who ordered the test, the results of the test. With respect to a child under three years of age, not later than twenty-four hours after the provider receives such results, the provider shall make reasonable efforts to notify the parent or guardian of the child of the blood lead analysis results. Any institution or laboratory making an accurate report in good faith shall not be liable for the act of disclosing such report to the Commissioner of Public Health or to the director of health. The commissioner shall determine the form and manner of transmission of data contained in such report.

(c) Each institution or laboratory that reports lead testing pursuant to this section shall, at least monthly, submit to the Commissioner of Public Health a comprehensive report that includes: (1) The name, full residence address, date of birth, gender, race and ethnicity of each person tested pursuant to subsection (b) of this section regardless of the level of lead in the blood; (2) the name, address and telephone number of the health care provider who ordered the test; (3) the sample collection date, analysis date, type and blood lead analysis result; (4) laboratory identifiers; and (5) such other information as the Commissioner of Public Health may require. Any institution or laboratory making an accurate report in good faith shall not be liable for the act of disclosing such report to the Commissioner of Public Health. The Commissioner of Public Health shall determine the form and manner of transmission of data contained in such report.

(d) Whenever an institutional laboratory or private clinical laboratory reporting blood lead tests pursuant to this section refers a blood lead sample to another laboratory for analysis, the laboratories may agree on which laboratory will report in compliance with subsections (b) and (c) of this section, but both laboratories shall be accountable to ensure that reports are made. The referring laboratory shall ensure that the requisition slip includes all of the information that is required in subsections (b) and (c) of this section and that this information is transmitted with the blood specimen to the laboratory performing the analysis.